These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12643615)

  • 1. Propafenone hepatotoxicity: report of two new cases.
    Cocozzella D; Curciarello J; Corallini O; Olivera A; Alburquerque MM; Fraquelli E; Zamagna L; Olenchuck A; Cremona A
    Dig Dis Sci; 2003 Feb; 48(2):354-7. PubMed ID: 12643615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propafenone hepatotoxicity: report of a new case and review of the literature.
    Younan LB; Barada KA; Faraj WG; Tawil AN; Jabbour MN; Khoury MY; El-Majzoub NM; Eloubeidi MA
    Saudi J Gastroenterol; 2013; 19(5):235-7. PubMed ID: 24045598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hepatic toxicity of propafenone: a case description].
    La Brocca A
    Ann Ital Med Int; 2002; 17(4):261-4. PubMed ID: 12532566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acute cholestatic hepatitis caused by propafenone. Report of a case and review of the literature].
    Gandolfi A; Rota E; Zanghieri G; Tolomelli S; Bagnulo A; Mengoli M
    Recenti Prog Med; 2001 Mar; 92(3):197-9. PubMed ID: 11320851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propafenone-related cholestatic hepatitis in an elderly patient.
    Grieco A; Forgione A; Giorgi A; Miele L; Gasbarrini G
    Ital Heart J; 2002 Jul; 3(7):431-4. PubMed ID: 12189974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Propafenone-induced liver injury: report of a case and review of the literature.
    Mondardini A; Pasquino P; Bernardi P; Aluffi E; Tartaglino B; Mazzucco G; Bonino F; Verme G; Negro F
    Gastroenterology; 1993 May; 104(5):1524-6. PubMed ID: 8482464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group.
    Chimienti M; Cullen MT; Casadei G
    Eur Heart J; 1995 Dec; 16(12):1943-51. PubMed ID: 8682031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs.
    Antman EM; Beamer AD; Cantillon C; McGowan N; Friedman PL
    J Am Coll Cardiol; 1990 Mar; 15(3):698-707. PubMed ID: 2303641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dydrogesterone-induced hepatitis and autoimmune hemolytic anemia.
    Altintaş E; Oğuz D; Kaçar S; Ozderin Y; Sezgin O; Zengin NI
    Turk J Gastroenterol; 2004 Mar; 15(1):49-52. PubMed ID: 15264122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Propafenone-induced liver injury.
    Spinler SA; Elder CA; Kindwall KE
    Ann Pharmacother; 1992; 26(7-8):926-8. PubMed ID: 1354511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Persistent atrial flutter induced by propafenone (Rytmonorm)].
    Fazekas T; Kiss J; Pap I; Rudas L
    Orv Hetil; 1994 Aug; 135(33):1819-22. PubMed ID: 8072758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses.
    Kochiadakis GE; Igoumenidis NE; Hamilos MI; Tzerakis PG; Klapsinos NC; Zacharis EA; Vardas PE
    Chest; 2004 Feb; 125(2):377-83. PubMed ID: 14769712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter.
    Antman EM; Beamer AD; Cantillon C; McGowan N; Goldman L; Friedman PL
    J Am Coll Cardiol; 1988 Oct; 12(4):1005-11. PubMed ID: 3417972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of paroxysmal atrial fibrillation recurrence using combined administration of propafenone and quinidine.
    Lau CP; Chow MS; Tse HF; Tang MO; Fan C
    Am J Cardiol; 2000 Dec; 86(12):1327-32. PubMed ID: 11113407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group.
    Podrid PJ; Anderson JL
    Am J Cardiol; 1996 Aug; 78(4):430-4. PubMed ID: 8752188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study.
    Azpitarte J; Alvarez M; Baún O; García R; Moreno E; Martín F; Tercedor L; Fernández R
    Eur Heart J; 1997 Oct; 18(10):1649-54. PubMed ID: 9347277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness.
    Wang J; Bourne GW; Wang Z; Villemaire C; Talajic M; Nattel S
    Circulation; 1993 Sep; 88(3):1030-44. PubMed ID: 8353865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-induced hepatitis with hepatic granuloma due to saridon.
    Abe M; Kumagi T; Nakanishi S; Yamagami T; Michitaka K; Abe K; Okura I; Yamashita H; Horiike N; Onji M
    J Gastroenterol; 2002; 37(12):1068-72. PubMed ID: 12522541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intravenous and oral propafenone in the treatment and prevention of paroxysmal atrial fibrillation].
    Cointe R; Metge M; Bru P; Vrancea F; Gerard R; Paganelli F; Lévy S
    Ann Cardiol Angeiol (Paris); 1993 Apr; 42(4):223-7. PubMed ID: 8517602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation.
    Reimold SC; Cantillon CO; Friedman PL; Antman EM
    Am J Cardiol; 1993 Mar; 71(7):558-63. PubMed ID: 8438741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.